KB-1787

Mouse IgG2a-LALAPG kappa, isotype Control

×
Please enable JavaScript in your browser to complete this form.
60303
Home » Antibodies » Mouse IgG2a-LALAPG kappa, isotype Control

Background of Mouse IgG2a-LALAPG kappa, isotype Control

Isotype controls are a type of primary antibodies that lack specificity to the target, but match the class and type of the primary antibody used in in vitro and in vivo studies. Isotype controls are often used to measure the level of non-specific background signal caused by binding non-specifically to Fc receptors on the cell surface, or other cellular molecules. Chinese hamster ovary (CHO) host cell line is the most popular mammalian system of therapeutic proteins production. The isotype controls produced by CHO line share similar posttranslational modifications with the therapeutic proteins, especially in N‐linked glycosylation, which are useful benchmark in the discovery and development of therapeutic antibodies.

Specifications

Catalog NumberKB-1787
Antibody NameMouse IgG2a-LALAPG kappa, isotype Control
IsotypeMouse IgG2a,kappa
FC MuationsL234A/L235A/P329G
TargetHEL
Species ReactivityChicken
Host Cell LineEXPI CHO
Purification MethodAffinity purified
Concentration>2 mg/mL
Formulation50 mM sodium citrate,150mM NaCl,pH5.5
Purity>95% by SDS-PAGE and SEC-HPLC
ValidationELISA
Endotoxin Level<0.2 EU/mg as determined by the LAL method
Sterility0.2μm filtered
StorageIt is recommended that the protein should be aliquoted for optimal storage.
Avoid repeated freeze-thaw cycles.
StabilityStable for twelve months from date of receipt when stored at -20°C to -80°C;
Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Kratz F, Elsadek B (July 2012). "Clinical impact of serum proteins on drug delivery". J Control Release. 161 (2): 429-45. doi:10.1016/j.jconrel.2011.11.028.
  2. "Notification of Approval to Manufacture and Market Nanozora® 30mg Syringes for S.C. Injection, a Therapy for Rheumatoid Arthritis, in Japan Japan's First NANOBODY® Therapeutic" (Press release). Taisho Pharmaceutical Holdings. September 26, 2022.
Please enable JavaScript in your browser to complete this form.